A hallucinogen found in magic mushrooms can “reset” the brains of people with lasting depression. It’s been proclaimed that the magic mushroom hallucinogen can “reset” distressed brains, giving great news for future treatment.
The mini experiment gave a number of patients one dose of the psychedelic ingredient psilocybin, resulting in half of the patients no longer being depressed along with up to five weeks of changes in their brain activity taking place.
Nevertheless, the specified amount of impact on brain activity wasn’t found, part of why the team at London’s Imperial College doesn’t recommend self-medicate. In addition, there has been mini studies happening in series indicating that the psychedelic ingredient could act as stimulant in playing a part in depression that only allows for a temporary escape of the symptoms and not a solution.
The team learned that psilocybin acted on two key areas of the brain (the amygdala and the default-mode network) after conducting fMRI brain scans prior to the treatment with psilocybin and the day afterwards when the patients were clearheaded.
In the part of our brain called the amygdala; substantially involved in how we operate our sentiments such as uneasiness and distress became less of a factor. The symptoms became more enhanced as the amygdala became less prevalent.
The team of various brain regions known as the default mode network became more controlled after taking psilocybin.
The head of psychedelic research at Imperial, Dr. Robin stated on the BBC website that patients were ready for drug and explained that the psychedelic encounter resets and basically frees up the depressed brain. Professor, Mitul Mehta, who professes at the Institute of Psychiatry at King’s College London also co-signed the legitimacy of the treatment: “What is impressive about these preliminary findings is that brain changes occurred in the networks we know are involved in depression, after just a single dose of psilocybin.”
However, before psilocybin is introduced to the market, larger studies would need to take place for it to be accepted as a suitable treatment for depression. The study, which has been published in the journal Scientific Reports has yet to conduct a control study with a group of “fit” minds or brains to have a contrast in order to be complete. The bright news is that this is indeed a promising remedy for the future and a possible win for the medical community.